Arcellx and Kite (Gilead) partner on CART-ddBCMA; $225M upfront + $100M equity; 100% ORR in Phase 1

Arcellx, Inc.

Arcellx receives $225M upfront cash and $100M equity investment from Gilead; eligible for up to $3.9B in milestones.
Phase 1 trial: 100% ORR (38 pts), 71% CR/sCR, 80% CR/sCR in patients dosed >12 months ago; no Grade≥3 CRS at RP2D.
Kite to manufacture after tech transfer; 50/50 U.S. profit split; low-to-mid teen royalties ex-U.S.; deal expected to close Q1 2023.
Gilead purchases 3,478,261 shares at $100M; standstill and registration rights agreed.
iMMagine-1 Phase 2 pivotal trial initiated; Phase 1 trial of ACLX-002 for AML/MDS also started.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcellx, Inc. entered into Collaboration Agreement with Kite Pharma, Inc., a Gilead Company valued at $225 million upfront cash payment (effective 2022-12-09).

Action: entry
Agreement: collaboration
Counterparty: Kite Pharma, Inc., a Gilead Company
Value: $225 million upfront cash payment
Effective: 2022-12-09

Exact text from the filing

On December 9, 2022, Arcellx, Inc. (“Arcellx”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Kite Pharma, Inc., a Gilead Company (“Kite”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcellx, Inc. entered into Common Stock Purchase Agreement with Gilead Sciences, Inc. valued at $100 million (effective 2022-12-09).

Action: entry
Agreement: equity purchase
Counterparty: Gilead Sciences, Inc.
Value: $100 million
Effective: 2022-12-09

Exact text from the filing

pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,478,261 shares of Arcelllx’s common stock (the “Shares”) for an aggregate purchase price of $100 million

View on SEC.gov

Browse all material agreements →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-301426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.